|
1
|
DeSantis CE, Fedewa SA, Goding Sauer A,
Kramer JL, Smith RA and Jemal A: Breast cancer statistics, 2015:
Convergence of incidence rates between black and white women. CA
Cancer J Clin. 66:31–42. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Finn RS, Crown JP, Lang I, Boer K,
Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, et
al: The cyclin-dependent kinase 4/6 inhibitor palbociclib in
combination with letrozole versus letrozole alone as first-line
treatment of oestrogen receptor-positive, HER2-negative, advanced
breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study.
Lancet Oncol. 16:25–35. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Coughlin SS and Ekwueme DU: Breast cancer
as a global health concern. Cancer Epidemiol. 33:315–318. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Swain SM, Baselga J, Kim SB, Ro J,
Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A,
Heeson S, et al CLEOPATRA Study Group, : Pertuzumab, trastuzumab,
and docetaxel in HER2-positive metastatic breast cancer. N Engl J
Med. 372:724–734. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Turner NC, Ro J, André F, Loi S, Verma S,
Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, et al
PALOMA3 Study Group, : Palbociclib in hormone-receptor-positive
advanced breast cancer. N Engl J Med. 373:209–219. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yu QC, Verheyen EM and Zeng YA: Mammary
development and breast cancer: A Wnt perspective. Cancers (Basel).
8:652016. View Article : Google Scholar
|
|
7
|
Collignon J, Lousberg L, Schroeder H and
Jerusalem G: Triple-negative breast cancer: Treatment challenges
and solutions. Breast Cancer (Dove Med Press). 8:93–107.
2016.PubMed/NCBI
|
|
8
|
Guo R, Lu G, Qin B and Fei B: Ultrasound
imaging technologies for breast cancer detection and management: A
Review. Ultrasound Med Biol. 44:37–70. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheng CW, Yu JC, Wang HW, Huang CS, Shieh
JC, Fu YP, Chang CW, Wu PE and Shen CY: The clinical implications
of MMP-11 and CK-20 expression in human breast cancer. Clin Chim
Acta. 411:234–241. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Clark A and Fallowfield LP: Breast cancer.
CRC Press. 2014.
|
|
11
|
Tadayyon H, Sadeghi-Naini A, Wirtzfeld L,
Wright FC and Czarnota G: Quantitative ultrasound characterization
of locally advanced breast cancer by estimation of its scatterer
properties. Med Phys. 41:0129032014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH
and Lee KH; Community of population-based Regional cancer
registries, : Cancer statistics in Korea: Incidence, mortality,
survival, and prevalence in 2014. Cancer Res Treat. 49:292–305.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Poortmans PM, Collette S, Kirkove C, Van
Limbergen E, Budach V, Struikmans H, Collette L, Fourquet A,
Maingon P, Valli M, et al EORTC Radiation Oncology, ; Breast Cancer
Groups: Internal mammary and medial supraclavicular irradiation in
breast cancer. N Engl J Med. 373:317–327. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tutt A, Ellis P, Kilburn L, Gilett C,
Pinder S and Abraham J: Abstract S3-01: the TNT trial: A randomized
phase III trial of carboplatin (C) compared with docetaxel (D) for
patients with metastatic or recurrent locally advanced triple
negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Res. 75
(Suppl 9):S3–S4. 2015.
|
|
15
|
Basset P, Bellocq JP, Lefebvre O, Noël A,
Chenard MP, Wolf C, Anglard P and Rio MC: Stromelysin-3: A paradigm
for stroma-derived factors implicated in carcinoma progression.
Crit Rev Oncol Hematol. 26:43–53. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bianchini G, Balko JM, Mayer IA, Sanders
ME and Gianni L: Triple-negative breast cancer: Challenges and
opportunities of a heterogeneous disease. Nat Rev Clin Oncol.
13:674–690. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Basset P, Bellocq JP, Wolf C, Stoll I,
Hutin P, Limacher JM, Podhajcer OL, Chenard MP, Rio MC and Chambon
P: A novel metalloproteinase gene specifically expressed in stromal
cells of breast carcinomas. Nature. 348:699–704. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Okada A, Saez S, Misumi Y and Basset P:
Rat stromelysin 3: cDNA cloning from healing skin wound, activation
by furin and expression in rat tissues. Gene. 185:187–193. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tan J, Buache E, Alpy F, Daguenet E,
Tomasetto CL, Ren GS and Rio MC: Stromal matrix
metalloproteinase-11 is involved in the mammary gland postnatal
development. Oncogene. 33:4050–4059. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schönbeck U, Mach F, Sukhova GK, Atkinson
E, Levesque E, Herman M, Graber P, Basset P and Libby P: Expression
of stromelysin-3 in atherosclerotic lesions: Regulation via
CD40-CD40 ligand signaling in vitro and in vivo. J Exp Med.
189:843–853. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Andarawewa KL, Motrescu ER, Chenard MP,
Gansmuller A, Stoll I, Tomasetto C and Rio MC: Stromelysin-3 is a
potent negative regulator of adipogenesis participating to cancer
cell-adipocyte interaction/crosstalk at the tumor invasive front.
Cancer Res. 65:10862–10871. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Motrescu ER and Rio MC: Cancer cells,
adipocytes and matrix metalloproteinase 11: A vicious tumor
progression cycle. Biol Chem. 389:1037–1041. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tan J, Buache E, Chenard MP, Dali-Youcef N
and Rio MC: Adipocyte is a non-trivial, dynamic partner of breast
cancer cells. Int J Dev Biol. 55:851–859. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hadler-Olsen E, Winberg JO and
Uhlin-Hansen L: Matrix metalloproteinases in cancer: Their value as
diagnostic and prognostic markers and therapeutic targets. Tumour
Biol. 34:2041–2051. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Benson CS, Babu SD, Radhakrishna S,
Selvamurugan N and Ravi Sankar B: Expression of matrix
metalloproteinases in human breast cancer tissues. Dis Markers.
34:395–405. 2013. View Article : Google Scholar : PubMed/NCBI
|
